RedHill Biopharma Ltd.
RDHLNASDAQHealthcare● Active
$1.02
$-0.01(-0.97%)
Market Cap$3205714
P/E Ratio—
52W High$3.31
52W Low$0.71
RedHill Biopharma Ltd. (RDHL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RDHL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.29M | $8.04M | $6.53M | $61.80M | $85.76M |
| Cost of Revenue | $0.00M | $3.19M | $3.46M | $33.34M | $49.41M |
| Gross Profit | $0.29M | $4.85M | $3.07M | $28.46M | $36.35M |
| Gross Margin %(computed) | 100.00% | 60.31% | 47.03% | 46.06% | 42.39% |
| Operating Expenses | |||||
| R&D Expenses | $2.02M | $1.59M | $3.53M | $7.28M | $29.50M |
| G&A Expenses | $6.17M | $14.52M | $28.88M | $54.97M | $76.60M |
| Total Operating Expenses | $8.20M | $19.46M | ($9.56M) | $71.31M | $117.49M |
| Operating Income | ($7.91M) | ($14.61M) | $12.63M | ($42.84M) | ($81.14M) |
| Operating Margin %(computed) | — | -181.69% | 193.45% | -69.33% | -94.61% |
| Interest Income | $0.02M | $0.13M | $0.09M | $0.14M | $0.05M |
| Interest Expense | $0.02M | $0.06M | $0.37M | $41.33M | $16.57M |
| Income Before Tax | ($8.08M) | ($8.27M) | $23.92M | ($71.67M) | ($97.74M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($0.43M) | ($8.27M) | $23.92M | ($71.67M) | ($97.74M) |
| Net Margin %(computed) | -150.00% | -102.80% | 366.25% | -115.97% | -113.98% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $-7.00 | $46.00 | $-600.00 | $-1000.00 |
| Wtd Avg Shares | 3.16M | 2.46M | 0.52M | 0.12M | 0.09M |
| EBITDA | ($7.65M) | ($7.59M) | $26.27M | ($22.18M) | ($63.03M) |
| EBITDA Margin %(computed) | — | -94.42% | 402.34% | -35.89% | -73.50% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more RedHill Biopharma Ltd. data
About RedHill Biopharma Ltd. (RDHL) Income Statement
RedHill Biopharma Ltd. (RDHL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RDHL reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.00B) — a net profit margin of -150.00%.
Frequently asked questions
RDHL · 4 questionsRedHill Biopharma Ltd. (RDHL) reported revenue of $0.00B for 2025, down 96.4% year-over-year.
RDHL revenueRDHL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09